검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | Anti-Thymocyte Globulin (Anti-Thymocyte Globulin) Sumitomo Pharma Switzerland GmbH·End Stage Renal Disease 76 trials·t½ 3 h |
|---|---|
Overview Program | Anti-Thymocyte Globulin |
Overview Company | Sumitomo Pharma Switzerland GmbH |
Overview Modality | ANTIBODY |
Overview Target | End Stage Renal Disease |
Overview Indication | Chronic Myeloproliferative Disorders; Leukemia |
Overview Phase | PHASE_2 |
Overview Status | ACTIVE |
MoA Mechanism | The mechanism of action by which polyclonal antilymphocyte preparations suppress immune responses is not fully understood |
MoA Biomarker | biomarkers |
PK/PD Half-life | 3 h |
PK/PD Species | Rabbit |
PK/PD Animal (cat.) | In vitro |
PK/PD Experiment | pharmacokinetic |
Toxicology Species | Rabbit |
Toxicology Animal (cat.) | Unknown |
Toxicology Major finding | thrombocytopenia have occurred with THYMOGLOBULIN administration ( 6 ) and require monitoring of |
Toxicology CRS | Reported |
Clinical OS | 49 |
Clinical Result source | ClinicalTrials.gov NCT01295710 |
Clinical Data Tier / Score | A · 35 |
Clinical Program phase | PHASE_2 |
Clinical Clinical sync | 2026년 7월 8일 (6일 전) |
검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | Anti-Thymocyte Globulin (Anti-Thymocyte Globulin) Sumitomo Pharma Switzerland GmbH·End Stage Renal Disease 76 trials·t½ 3 h |
|---|---|
Overview Program | Anti-Thymocyte Globulin |
Overview Company | Sumitomo Pharma Switzerland GmbH |
Overview Modality | ANTIBODY |
Overview Target | End Stage Renal Disease |
Overview Indication | Chronic Myeloproliferative Disorders; Leukemia |
Overview Phase | PHASE_2 |
Overview Status | ACTIVE |
MoA Mechanism | The mechanism of action by which polyclonal antilymphocyte preparations suppress immune responses is not fully understood |
MoA Biomarker | biomarkers |
PK/PD Half-life | 3 h |
PK/PD Species | Rabbit |
PK/PD Animal (cat.) | In vitro |
PK/PD Experiment | pharmacokinetic |
Toxicology Species | Rabbit |
Toxicology Animal (cat.) | Unknown |
Toxicology Major finding | thrombocytopenia have occurred with THYMOGLOBULIN administration ( 6 ) and require monitoring of |
Toxicology CRS | Reported |
Clinical OS | 49 |
Clinical Result source | ClinicalTrials.gov NCT01295710 |
Clinical Data Tier / Score | A · 35 |
Clinical Program phase | PHASE_2 |
Clinical Clinical sync | 2026년 7월 8일 (6일 전) |
추천 비교
추천 비교